抄録
Bleomycin was administered to 14 patients with malignant lymphoma (5 cases of reticulum cell sarcoma, 6 cases of Hodgkin's disease, 1 cases of lymphosarcoma and 2 cases of histologically unclassifed type). The drug was also given to 9 patients with leukemia.
In 10 of the 12 cases of malignant lymphoma enlarged lymph nodes clearly shrank after single Bleomycin administration. And a remarkable effect appeared promptly in 5 of them. These results indicated that Bleomycin might well be used as a remission inducer. In some cases of leukemia treated with Bleomycin the leukocyte counts were decreased, but its life-prolongation effect in leukemic cases needed further observation. Attention should be paid for its side effects in lung. Combination treatment with Bleomycin and fibroblast-inhibiting agents (CPBP) was useful for remission as well as for prevention of pulmonary disturbances. The use of Bleomycin in the treatment of malignant lymphoma was expected to improve the chemotherapy result in this disease.
